Scholarlink

<p>Ischemic brain injury is the leading cause of neurological disability and death worldwide. Adenosine A2B receptor (A2BR) is a member of the G protein-coupled receptor family, playing a crucial role in regulating excitotoxicity, inflammation, cell apoptosis, and vascular homeostasis. New evidence suggests that adenosine A2BR has a biphasic, time-dependent effect on ischemic brain injury. Its antagonists exhibit neuroprotective effects in the acute phase, while agonists have anti-inflammatory and vascular protective effects in the later stage, providing a new therapeutic direction for improving the long-term prognosis of patients with ischemic brain injury. This article reviews the research progress of A2BR in ischemic brain injury, including its molecular structure, expression kinetics, cell distribution, mechanism of action, pharmacological intervention, and systemic significance. We also discussed the therapeutic prospects of targeting A2BR and provided future prospects for personalized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The biphasic regulatory effect of adenosine A2B receptor in ischemic brain injury and its therapeutic potential

  • 期刊论文

  • 发表日期：

    2026年3月9日

查看全文
  • Xu Rui,
  • Wang Xi,
  • Li Mengzhu,
  • Su Peiwei,
  • Liu Mudong,
  • Zhu Chao,
  • Luo Wanyu,
  • Zhao Haijun

摘要

Ischemic brain injury is the leading cause of neurological disability and death worldwide. Adenosine A2B receptor (A2BR) is a member of the G protein-coupled receptor family, playing a crucial role in regulating excitotoxicity, inflammation, cell apoptosis, and vascular homeostasis. New evidence suggests that adenosine A2BR has a biphasic, time-dependent effect on ischemic brain injury. Its antagonists exhibit neuroprotective effects in the acute phase, while agonists have anti-inflammatory and vascular protective effects in the later stage, providing a new therapeutic direction for improving the long-term prognosis of patients with ischemic brain injury. This article reviews the research progress of A2BR in ischemic brain injury, including its molecular structure, expression kinetics, cell distribution, mechanism of action, pharmacological intervention, and systemic significance. We also discussed the therapeutic prospects of targeting A2BR and provided future prospects for personalized treatment strategies.